Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MoonLake Immunotherapeutics (NASDAQ: MLTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as it develops sonelokimab, an investigational Nanobody® targeting IL‑17A and IL‑17F, for inflammatory skin and joint diseases. As a Cayman Islands–incorporated issuer listed on Nasdaq, MoonLake files reports and current event disclosures with the Securities and Exchange Commission that document material agreements, clinical milestones and financial results.
Among the key documents are Form 8‑K filings, which MoonLake uses to report material events such as the pricing of an underwritten offering of Class A ordinary shares, entry into a term loan facility, and press releases announcing quarterly financial results. 8‑K filings also reference clinical and regulatory developments, including Phase 3 VELA trial data in hidradenitis suppurativa (HS), Phase 2 LEDA results in palmoplantar pustulosis (PPP), interim analyses from the VELA‑TEEN adolescent HS study, and updates on the broader sonelokimab trial portfolio.
Investors can use this page to review how MoonLake describes its financial condition, capital structure and key agreements in official SEC documents. Filings may incorporate press releases that summarize cash balances, research and development spending, non-dilutive financing arrangements, and expectations regarding the funding of Phase 2 and Phase 3 programs in HS, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and PPP.
Stock Titan enhances these filings with AI-powered tools that help interpret lengthy disclosures. Users can quickly identify the purpose of a given 8‑K, locate references to clinical trial data, and understand the context of equity offerings or debt facilities. Real-time updates from EDGAR ensure that new MoonLake filings appear promptly, while structured access makes it easier to follow how regulatory, clinical and financing developments are reflected in the company’s official record.
MoonLake Immunotherapeutics is asking shareholders to vote at its 2026 Annual General Meeting on June 4, 2026 in New York. Shareholders will elect Class I director nominee Spike Loy, ratify Baker Tilly US, LLP as independent auditor for 2026, and cast an advisory say-on-pay vote on executive compensation.
The key item is approval of an amended and restated 2022 Equity Incentive Plan. The plan would add 5,000,000 Class A Ordinary Shares for awards, bringing the total share pool to 9,353,948 and representing potential dilution of about 6.2% as of April 1, 2026. It also extends the plan term to June 4, 2036, adds a one-year minimum vesting requirement (with limited exceptions), adjusts non-employee director compensation limits, removes liberal share recycling, and clarifies change-in-control treatment.
As of the April 9, 2026 record date, there were 72,852,170 Class A Ordinary Shares outstanding, each entitled to one vote. The proxy describes MoonLake’s governance framework, board and committee structure, director independence, and executive pay philosophy. The Compensation Committee notes 99% support for the prior say-on-pay vote and that named executive officers waived 2025 cash bonuses despite achieving corporate goals.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 2,426 Class A ordinary shares in an open-market transaction. The shares were sold on April 14, 2026 at a weighted average price of $19.56 per share, in multiple trades between $19.50 and $19.625.
After this transaction, he directly holds 1,186,084 Class A ordinary shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance rather than timed discretionarily.
MoonLake Immunotherapeutics Chief Executive Officer Jorge Santos da Silva reported open-market sales of 150,000 Class A ordinary shares of the company. The transactions occurred on April 10 and April 13 at weighted average prices of $18.41 and $18.23 per share, respectively, in multiple trades within disclosed price ranges. Following these sales, he continues to hold 2,924,893 Class A ordinary shares directly. The sales were made pursuant to Rule 144 under the Securities Act, indicating resales of already-owned shares under an established exemption.
MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt reported open-market sales of Class A ordinary shares under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025 to cover his tax liabilities.
He sold 85,870 shares on April 9, 2026 at a weighted average price of $18.94 per share and 1,925 shares on April 10, 2026 at a weighted average price of $19.51 per share, for total reported sales of 87,795 shares. Following these transactions, he directly holds 1,188,510 Class A ordinary shares.
MoonLake Immunotherapeutics submitted a Form 144 notice concerning proposed sales of Class A common shares. The filing lists a 150,000 share figure alongside account and outstanding figures and shows 3,027,483 shares obtained upon exchange on 10/01/2023.
The filing names UBS Financial Services Inc. as the broker and includes a filing date of 04/10/2026. The excerpt does not state prices, planned sale timing, or proceeds treatment.
MLTX notice reports proposed sales of Common stock under Form 144 by a broker-dealer entry for UBS Financial Services, Inc. The excerpt lists proposed transactions including 150,000 shares on 04/05/2023 (exchange of share) and a 10,870-share purchase on 10/08/2025. A securities count of 71,727,875 is shown with date 04/09/2026.
MoonLake Immunotherapeutics’ major shareholder group affiliated with BVF Partners reported substantial open-market sales of Class A Ordinary Shares. On March 31, 2026, the reporting entities sold a combined 3,750,000 shares at $16.79 per share in multiple transactions.
The filing is made jointly by several funds and entities in a Section 13(d) group that collectively owns more than 10% of MoonLake’s common stock, each disclaiming beneficial ownership beyond its pecuniary interest. After these sales, individual reporting entities still report multi‑million share holdings.
The group also reports indirect holdings of three “Option to Buy” awards over 6,682, 7,688 and 11,297 Class A Ordinary Shares with exercise prices of $48.83, $42.44 and $29.18, expiring in 2035, 2034 and 2033 respectively. Two options are fully vested, while the 6,682‑share grant will vest in full by June 5, 2026 or at the next annual general meeting, subject to Spike Loy’s continued service.
MoonLake Immunotherapeutics’ major shareholder group BVF and affiliates report owning 16,001,284 Class A ordinary shares, or about 22.3% of the 71,727,875 shares outstanding as of February 1, 2026. The holdings are spread across several BVF funds and a managed account.
On March 31, 2026, BVF sold 1,932,354 shares at $16.79 per share, BVF II sold 1,569,116 shares at $16.79, and Biotechnology Value Trading Fund OS sold 248,530 shares at $16.79. Despite these sales, the BVF complex remains a large beneficial owner with shared voting and dispositive power across its entities.
The filing discloses a proposed sale of 3,750,000 shares of Common Stock on NASDAQ. The record shows an aggregate offering price of $63,487,500.00 and a reported position of 71,727,875 shares with an as of date of 03/31/2026. The shares include 18,501,284 shares identified as merger consideration acquired on 04/05/2022.